CREM gene – Talk Bio

ICER Report Highlights Unjustified Price Hikes on Five Brand-Name Drugs, Costing U.S. $815 Million in 2023

4 months ago talkbio0Tagged Biktarvy, Cabometyx, CREM gene, Darzalex, drug price, Entresto, Increased, Johnson & Johnson, Novartis, pharmaceutical companies, Prices

ICER, unsupported price increases, drug price hikes, pharmaceutical companies, Gilead Sciences, Johnson & Johnson, Novartis, Biktarvy, Darzalex, Entresto, Cabometyx, Xeljanz.

ICER Report Highlights $815 Million in Unjustified Drug Price Increases in 2023

4 months ago talkbio0Tagged 2023, CREM gene, drug price, Health care facility, pharmaceutical costs, Report (document)

ICER report, unsupported drug price hikes, 2023, pharmaceutical costs, healthcare spending

ICER Report Suggests Significant Price Reduction for Pfizer’s ATTR-CM Drug Tafamidis

6 months ago talkbio0Tagged ATTR-CM, Cost-Effectiveness, CREM gene, ICER, Pricing, tafamidis

Tafamidis, ATTR-CM, ICER, Pricing, Cost-Effectiveness

Lykos Faces Setback as ICER Concludes Insufficient Evidence for MDMA-Based PTSD Treatment

10 months ago talkbio0Tagged Approved, Clinical Trials, CREM gene, Evidence, Inadequate (qualifier), Lykos ', Midomafetamine, Post-Traumatic Stress Disorder, United States Food and Drug Administration

Lykos Therapeutics, MDMA, PTSD, ICER, Insufficient Evidence, Clinical Trials, FDA Approval

ICER Raises Concerns Over Uncertainties in Lykos MDMA Clinical Trials Ahead of FDA Advisory Committee Meeting

11 months ago talkbio0Tagged AdComm, Advisory Committees, Clinical Trials, CREM gene, Lykos ', Midomafetamine, Uncertainty, United States Food and Drug Administration

ICER, Lykos, MDMA, clinical trials, uncertainties, FDA, AdComm, advisory committee meeting